<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02348203</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-00061</org_study_id>
    <secondary_id>NCI-2015-00061</secondary_id>
    <secondary_id>N01-CN-2012-00031</secondary_id>
    <secondary_id>1403269898</secondary_id>
    <secondary_id>UAZ2013-02-01</secondary_id>
    <secondary_id>N01CN00031</secondary_id>
    <secondary_id>P30CA023074</secondary_id>
    <nct_id>NCT02348203</nct_id>
  </id_info>
  <brief_title>Aspirin and Zileuton and Biomarker Expression in Nasal Tissue of Current Smokers</brief_title>
  <official_title>Clinical Study of the Effect of Combined Treatment of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies the effects of aspirin and zileuton on genes related
      to tobacco use in current smokers. Aspirin and zileuton may interfere with genes related to
      tobacco use and may be useful in preventing lung cancer in current smokers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To analyze the impact of combined treatment of acetylsalicylic acid (ASA) (aspirin) and
      zileuton on smoking-related gene expression signature in the nasal epithelium in current
      smokers and to analyze any difference between the ASA and zileuton intervention and placebo
      control.

      SECONDARY OBJECTIVES:

      I. To assess the impact of ASA and zileuton on three lung cancer gene signatures (an 80-gene
      bronchial signature, a phosphatidylinositol 3-kinase [PI3K] pathway gene signature and a
      nasal diagnostic gene signature) and to compare this to placebo control.

      II. To determine whether the change in the smoking-related gene expression signature and the
      three lung cancer gene signatures of nasal epithelium persists 10-14 days off agent
      intervention.

      III. To measure urinary prostaglandin E metabolite (PGE-M) and leukotriene E(4) (LTE[4])
      levels in current smokers after ASA and zileuton.

      IV. To assess the safety in current smokers of 12 week exposure to ASA and zileuton.

      V. To evaluate a gender effect in the modulatory effects of ASA and zileuton on smoking
      related-gene expression signature.

      VI. To explore the effect of ASA and zileuton on the metabolomics profile of the arachidonic
      acid pathway.

      VII. To explore, in a discovery-driven fashion, the effect of ASA and zileuton on
      whole-genome gene expression.

      VIII. To analyze the impact of ASA and zileuton on karyometric analysis of buccal cells.

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive aspirin orally (PO) once daily (QD) and zileuton PO twice daily (BID)
      for 12 weeks in the absence of unacceptable toxicity.

      ARM II: Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.

      After completion of study treatment, patients are followed up for 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 13, 2016</start_date>
  <primary_completion_date type="Actual">February 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers After Acetylsalicylic Acid (ASA) and Zileuton Intervention</measure>
    <time_frame>Baseline to 12 weeks (End-of-intervention)</time_frame>
    <description>Change in a nasal smoking-related gene expression signature score derived from prior research was compared between the two study arms. Prior research showed that a higher score was observed in never smokers compared to current smokers. An increased score implicated a more favorable intervention effect. There is no minimum or maximum score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Impact of ASA and Zileuton on Three Lung Cancer Gene Signatures (an 80-gene Bronchial Signature, a PI3K Pathway Gene Signature and a Nasal Diagnostic Gene Signature)</measure>
    <time_frame>Up to week 12</time_frame>
    <description>Analysis of variance will be performed to evaluate whether ASA and zileuton has significantly different impact on changes in the three lung cancer gene signatures and the changes are significantly different from the placebo group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Smoking-related Gene Expression Signature</measure>
    <time_frame>Baseline to 14 days post intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the Three Lung Cancer Gene Signatures of Nasal Epithelium</measure>
    <time_frame>Baseline to 14 days post intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary PGE-M Levels</measure>
    <time_frame>Baseline up to week 12</time_frame>
    <description>Two sample t tests will be performed to evaluate whether or not there are significant differences in changes in PGE-M between the treatment and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary LTE (4) Levels</measure>
    <time_frame>Baseline up to week 12</time_frame>
    <description>Two sample t tests will be performed to evaluate whether or not there are significant differences in changes in LTE(4) between the treatment and placebo groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0</measure>
    <time_frame>Up to 2 weeks post-treatment</time_frame>
    <description>Descriptive statistics of the type and frequency of all adverse events will be generated, including 95% confidence intervals. For each type of the adverse events, a Fisher's exact test will be performed to compare the frequency of the adverse event between the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gender Effect on Smoking-related Gene Expression Signature</measure>
    <time_frame>Up to week 12</time_frame>
    <description>Exploratory analyses will be performed to evaluate whether the effect of ASA and zileuton on smoking-related gene expression signature is modulated by gender.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the Metabolomics Profile of the Arachidonic Acid Pathway</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Two sample t tests will be performed to evaluate whether or not there are significant differences in changes in oxylipin metabolome between the treatment and placebo groups. In addition, system biology methods will also be used to analyze the oxylipin metabolome data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole-genome Gene Expression</measure>
    <time_frame>Up to week 12</time_frame>
    <description>Pair-wise comparisons based on two-sample t tests will be performed to whole-genome gene expression data to identify the genes for which ASA and zileuton has a significantly different expression level from the placebo group. Multivariate statistical techniques such as principle component analysis (PCA) will be used to reduce complexity of the whole-genome expression data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of ASA and Zileuton on Karyometric Analysis of Buccal Cells</measure>
    <time_frame>Up to week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Arm I (aspirin, zileuton)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (double placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (aspirin, zileuton)</arm_group_label>
    <other_name>Acetylsalicylic Acid</other_name>
    <other_name>ASA</other_name>
    <other_name>Aspergum</other_name>
    <other_name>Ecotrin</other_name>
    <other_name>Empirin</other_name>
    <other_name>Entericin</other_name>
    <other_name>Extren</other_name>
    <other_name>Measurin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (aspirin, zileuton)</arm_group_label>
    <arm_group_label>Arm II (double placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given aspirin placebo PO</description>
    <arm_group_label>Arm II (double placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Administration</intervention_name>
    <description>Given zileuton placebo PO</description>
    <arm_group_label>Arm II (double placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zileuton</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (aspirin, zileuton)</arm_group_label>
    <other_name>Zyflo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current tobacco smokers with &gt;= 20 pack years of self-reported smoking exposure and an
             average use of &gt;= 10 cigarettes/day

          -  Karnofsky &gt;= 70%

          -  Leukocytes &gt;= 3,000/microliter

          -  Absolute neutrophil count &gt;= 1,500/microliter

          -  Hematocrit &gt;= the lower institutional limit

          -  Platelets &gt;= the lower institutional limits

          -  Total bilirubin within normal institutional limits

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             within normal institutional limits

          -  Creatinine =&lt; the upper institutional limits

          -  Prothrombin time (PT)/partial thromboplastin time (PTT) within normal institutional
             limits

          -  Fertile subjects must use adequate contraception (abstinence, barrier methods, or
             birth control pills) prior to study entry and for the duration of study participation;
             women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry and for
             the duration of study participation; should a woman become pregnant or suspect she is
             pregnant while participating in this study, she should inform her study physician
             immediately

          -  Participants may have a history of indeterminate pulmonary nodule(s) by chest imaging
             if nodule follow-up has been completed or the study procedures would not interfere
             with nodule follow-up

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  History of allergic reaction to aspirin or attributed to compounds of similar chemical
             or biologic composition to aspirin, including other nonsteroidal anti-inflammatory
             drugs (NSAIDs)

          -  Gastric intolerance attributable to ASA or NSAIDs

          -  History of gastric ulcer within the past 5 years (with or without bleeding)

          -  Use of ASA or NSAIDs for more than 5 days per month within 3 months of enrollment

          -  Not willing or are unable to refrain from use of any non-study ASA, NSAIDs and
             leukotriene antagonists during the study period

          -  Adult asthma

          -  Chronic, current or recent (within the past three months) use of leukotriene
             antagonists

          -  Require chronic anticoagulation or anti-platelet therapy

          -  History of bleeding disorder or hemorrhagic stroke

          -  Chronic, current or recent (within the past three months) use of glucocorticoids
             (systemic, topical and/or nasal sprays or steroid topical creams to large body surface
             area); use of steroid topical creams for small body areas (=&lt; 10% body surface) during
             study intervention is allowed

          -  History of chronic sinusitis or recent nasal polyps

          -  History of, or current, active or chronic liver disease even if transaminases have
             normalized

          -  History of allergic reaction to zileuton or attributed to compounds of similar
             chemical or biologic composition to zileuton

          -  Are taking drugs known to interact with zileuton, including theophylline, warfarin,
             and propranolol

          -  Not willing or are unable to limit alcohol consumption to =&lt; 2 alcoholic beverages a
             day during the study period

          -  Pregnant or lactating women; breastfeeding should be discontinued if the mother is
             treated with aspirin; should a woman become pregnant or suspect she is pregnant while
             participating in this study, she should inform her study physician immediately

          -  Participants may not be receiving any other investigational agents

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Have a known history of inability to absorb an oral agent

          -  Invasive cancer within the past five years except non-melanoma skin cancer

          -  Urine cotinine level, if collected at screening, does not confirm active smoking
             status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda L Garland</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Arizona Medical Center-University Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Banner University Medical Center - Tucson</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 27, 2015</study_first_submitted>
  <study_first_submitted_qc>January 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2015</study_first_posted>
  <results_first_submitted>March 3, 2020</results_first_submitted>
  <results_first_submitted_qc>March 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2020</results_first_posted>
  <last_update_submitted>May 2, 2020</last_update_submitted>
  <last_update_submitted_qc>May 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Zileuton</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT02348203/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Arm I (Aspirin, Zileuton)</title>
          <description>Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
Aspirin: Given PO
Laboratory Biomarker Analysis: Correlative studies
Zileuton: Given PO</description>
        </group>
        <group group_id="P2">
          <title>Arm II (Double Placebo)</title>
          <description>Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
Laboratory Biomarker Analysis: Correlative studies
Placebo Administration: Given aspirin placebo PO
Placebo Administration: Given zileuton placebo PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (Aspirin, Zileuton)</title>
          <description>Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
Aspirin: Given PO
Laboratory Biomarker Analysis: Correlative studies
Zileuton: Given PO</description>
        </group>
        <group group_id="B2">
          <title>Arm II (Double Placebo)</title>
          <description>Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
Laboratory Biomarker Analysis: Correlative studies
Placebo Administration: Given aspirin placebo PO
Placebo Administration: Given zileuton placebo PO</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="63"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.6" spread="8.6"/>
                    <measurement group_id="B2" value="53.5" spread="10.7"/>
                    <measurement group_id="B3" value="51.6" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers After Acetylsalicylic Acid (ASA) and Zileuton Intervention</title>
        <description>Change in a nasal smoking-related gene expression signature score derived from prior research was compared between the two study arms. Prior research showed that a higher score was observed in never smokers compared to current smokers. An increased score implicated a more favorable intervention effect. There is no minimum or maximum score.</description>
        <time_frame>Baseline to 12 weeks (End-of-intervention)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Aspirin, Zileuton)</title>
            <description>Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
Aspirin: Given PO
Laboratory Biomarker Analysis: Correlative studies
Zileuton: Given PO</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Double Placebo)</title>
            <description>Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
Laboratory Biomarker Analysis: Correlative studies
Placebo Administration: Given aspirin placebo PO
Placebo Administration: Given zileuton placebo PO</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in a Smoking-related Gene Expression Signature Score in the Nasal Epithelium of Current Smokers After Acetylsalicylic Acid (ASA) and Zileuton Intervention</title>
          <description>Change in a nasal smoking-related gene expression signature score derived from prior research was compared between the two study arms. Prior research showed that a higher score was observed in never smokers compared to current smokers. An increased score implicated a more favorable intervention effect. There is no minimum or maximum score.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="2.89"/>
                    <measurement group_id="O2" value="0.26" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of ASA and Zileuton on Three Lung Cancer Gene Signatures (an 80-gene Bronchial Signature, a PI3K Pathway Gene Signature and a Nasal Diagnostic Gene Signature)</title>
        <description>Analysis of variance will be performed to evaluate whether ASA and zileuton has significantly different impact on changes in the three lung cancer gene signatures and the changes are significantly different from the placebo group.</description>
        <time_frame>Up to week 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Smoking-related Gene Expression Signature</title>
        <time_frame>Baseline to 14 days post intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in the Three Lung Cancer Gene Signatures of Nasal Epithelium</title>
        <time_frame>Baseline to 14 days post intervention</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary PGE-M Levels</title>
        <description>Two sample t tests will be performed to evaluate whether or not there are significant differences in changes in PGE-M between the treatment and placebo groups.</description>
        <time_frame>Baseline up to week 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Urinary LTE (4) Levels</title>
        <description>Two sample t tests will be performed to evaluate whether or not there are significant differences in changes in LTE(4) between the treatment and placebo groups.</description>
        <time_frame>Baseline up to week 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Adverse Events Graded Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0</title>
        <description>Descriptive statistics of the type and frequency of all adverse events will be generated, including 95% confidence intervals. For each type of the adverse events, a Fisher's exact test will be performed to compare the frequency of the adverse event between the two groups.</description>
        <time_frame>Up to 2 weeks post-treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gender Effect on Smoking-related Gene Expression Signature</title>
        <description>Exploratory analyses will be performed to evaluate whether the effect of ASA and zileuton on smoking-related gene expression signature is modulated by gender.</description>
        <time_frame>Up to week 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in the Metabolomics Profile of the Arachidonic Acid Pathway</title>
        <description>Two sample t tests will be performed to evaluate whether or not there are significant differences in changes in oxylipin metabolome between the treatment and placebo groups. In addition, system biology methods will also be used to analyze the oxylipin metabolome data.</description>
        <time_frame>Baseline to week 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Whole-genome Gene Expression</title>
        <description>Pair-wise comparisons based on two-sample t tests will be performed to whole-genome gene expression data to identify the genes for which ASA and zileuton has a significantly different expression level from the placebo group. Multivariate statistical techniques such as principle component analysis (PCA) will be used to reduce complexity of the whole-genome expression data.</description>
        <time_frame>Up to week 12</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of ASA and Zileuton on Karyometric Analysis of Buccal Cells</title>
        <time_frame>Up to week 12</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from the time that the first dose of study drug was taken until 2 weeks after participants come off the 12-week agent intervention.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Arm I (Aspirin, Zileuton)</title>
          <description>Patients receive aspirin PO QD and zileuton PO BID for 12 weeks in the absence of unacceptable toxicity.
Aspirin: Given PO
Laboratory Biomarker Analysis: Correlative studies
Zileuton: Given PO</description>
        </group>
        <group group_id="E2">
          <title>Arm II (Double Placebo)</title>
          <description>Patients receive aspirin placebo PO QD and zileuton placebo PO BID for 12 weeks.
Laboratory Biomarker Analysis: Correlative studies
Placebo Administration: Given aspirin placebo PO
Placebo Administration: Given zileuton placebo PO</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sherry Chow</name_or_title>
      <organization>University of Arizona</organization>
      <phone>520-626-3358</phone>
      <email>schow@azcc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

